| Drug class | Target | Study entities | Approved for |
| Anti-VEGF strategies | | | | Bevacizumab (Avastin) | VEGF-A | AML, MDS, CLL, CML, NHL, MM | Metastatic colorectal cancer, NSCLC, breast cancer |
| RTK inhibitors | | | | Vatalanib | VEGFR1-3, PDGFRβ, CD117 | AML, PMF, MDS, CML, DLBCL, MM | | Cediranib (Recentin) | VEGFR1-3, PDGFRβ, CD117 | AML, MDS, CLL | |
| Immunomodulators | | | | Thalidomide | | AML, MDS, MPN, CLL, NHL, MM | MM | Lenalidomide (Revlimid) | | AML, MDS, CLL, NHL | MM, 5q-MDS |
|
|